Abstract
There have been many advances in the prevention and treatment of GVHD, including cyclosporine, FK506, and combination therapies. This syndrome, however, continues to account for significant morbidity and mortality after allogeneic transplantation. With the expanded use of matched unrelated as well as mismatched related donors, the increase in incidence and severity of GVHD poses a new clinical challenge. Many of the newer agents discussed in this paper may have a role in the future as therapy for acute GVHD. The evaluation of these new agents and the approach to be taken is hampered by the realization that most patients have received and are relatively refractory to standard therapies. Clinical trials must be performed earlier in the course of the syndrome to establish the role of these compounds. Newer strategies are likely to include the use of sequential therapy directed at blocking endogenous cytokines followed by blocking alloreactive donor cells, and immunologic advances such as the induction of tolerance. What impact, if any, such therapy may have on amelioration of a graft-versus-leukemia effect remains unknown.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lazarus, H., Vogelsang, G. & Rowe, J. Prevention and treatment of acute graft-versus-host disease: the old and the new. A report from The Eastern Cooperative Oncology Group (ECOG). Bone Marrow Transplant 19, 577–600 (1997). https://doi.org/10.1038/sj.bmt.1700710
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1700710
Keywords
This article is cited by
-
Omission of day-11 MTX, in combination with tacrolimus, is not associated with increased risk of acute graft-versus-host disease after allo-BMT
Bone Marrow Transplantation (2013)
-
Prophylaxis regimens for GVHD: systematic review and meta-analysis
Bone Marrow Transplantation (2009)
-
Cyclosporin, methotrexate and prednisolone for graft-versus-host disease prophylaxis in allogeneic peripheral blood progenitor cell transplants
Bone Marrow Transplantation (2008)
-
Bone marrow transplant cure for β-thalassaemia major: initial experience from a developing country
Annals of Hematology (2008)
-
Long-term outcomes of adults with acute lymphoblastic leukemia after autologous or unrelated donor bone marrow transplantation: a comparative analysis by the National Marrow Donor Program and Center for International Blood and Marrow Transplant Research
Bone Marrow Transplantation (2008)